From theTimes
January 26, 2008
In the know
Gilts
Rumour of the day
Drug industry chat is that America’s Biogen, which tried but failed to sell itself last year at the prompting of the activist shareholder Carl Icahn, may be pondering a bid for Genmab, a €2 billion Danish biotech group trialling HuMax, a leukaemia treatment. GlaxoSmithKline has the licence for this drug and may have to counterbid to protect its position.